Atazanavir-d 6

Overview

Atazanavir-d 6 is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4 , and an inhibitor and inducer of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC 50 of 3.49 μM.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Others | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Cytochrome P450 | Products > Signaling Pathways > P-glycoprotein | Products > Signaling Pathways > Endogenous Metabolite | Products > Signaling Pathways > Isotope-Labeled Compounds | Products > Signaling Pathways > HIV | Products > Signaling Pathways > HIV Protease | Products > Signaling Pathways > SARS-CoV

Product Information

• Catalog No.: HY-17367S4
• CAS No.: 1092540-50-5
• Molecular Formula: C38H46D6N6O7
• Molecular Weight: 710.89
• Purity: 99.28%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source